NCT04311034View on ClinicalTrials.gov

A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 26, 2018

Primary Completion Date

December 21, 2021

Study Completion Date

May 30, 2022

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

RC48

Participants will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, investigators believed that the subject could no longer benefit from treatment, or this study ended.

Trial Locations (1)

200433

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY

NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter